Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have been assigned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the […]
CAMBRIDGE, Mass., Oct. 31, 2023 Fulcrum Therapeutics, Inc.® , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients